Buy Now
$4,123 $4,850
15% off
$4,840 $6,050
20% off
$5,845 $8,350
30% off
Buy now
Premium Report Details
Base Year: 2023
Companies covered: 15
Tables & Figures: 284
Countries covered: 23
Pages: 159
Download Free PDF
Erythropoietin Drugs Market
Get a free sample of this report
Get a free sample of this report Erythropoietin Drugs Market
Is your requirement urgent? Please give us your business email for a speedy delivery!
Erythropoietin Drugs Market Size
Erythropoietin Drugs Market size was valued at around USD 10.4 billion in 2023 and is estimated to grow at 4.5% CAGR from 2024 to 2032. Erythropoietin drugs are medications designed to stimulate the production of red blood cells (RBCs) in the body. They mimic the action of erythropoietin, a naturally occurring hormone produced by the kidneys that regulates red blood cell production. These drugs are primarily used to treat conditions characterized by anemia, which is a deficiency of red blood cells.
The rising prevalence of cancer is a significant driving factor for the market. For instance, according to the World Health Organization (WHO), in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths worldwide. Thus, this underscores the growing demand for erythropoietin drugs, as they are essential in managing anemia associated with cancer treatments, helping to improve patient outcomes and quality of life.
Furthermore, rising prevalence of chronic kidney disease (CKD), advancements in drug formulations, and rising geriatric population are the promoting factors advancing the growth of the market.